doi:10.3969/j.issn.1004-583X.2023.05.014

Abstract

CLC Number:

R541.6

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.05.014

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I5/459

References 53

[1]	Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A report from the American Heart Association[J]. Circulation, 2023, 147(8):e93-e621.
[2]	Van Nuys KE, Xie Z, Tysinger B, et al. Innovation in heart failure treatment: Life expectancy, disability, and health disparities[J]. JACC Heart Fail, 2018, 6(5):401-409. doi: 10.1016/j.jchf.2017.12.006 URL
[3]	Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis[J]. Circ Heart Fail, 2021, 14(10):e008406.
[4]	Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010, 50(4): 401-414. doi: 10.1177/0091270009343932 URL
[5]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[6]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6):e137-e161.
[7]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018, 46(10):760-789.
[8]	Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail, 2022, 28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010 pmid: 35378257
[9]	Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J]. Eur Heart J, 2015, 36(30):1990-1997. doi: 10.1093/eurheartj/ehv186 pmid: 26022006
[10]	Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019, 108(10):1074-1082. doi: 10.1007/s00392-019-01440-y pmid: 30788621
[11]	张常莹, 刘晓宇, 李晓燕, 等. 沙库巴曲缬沙坦对植入了心脏除颤器的心力衰竭患者室性心律失常发生的影响[J]. 中国心脏起搏与心电生理杂志, 2021, 35(4):305-309.
[12]	Russo V, Ammendola E, Gasperetti A, et al. Add-on therapy with sacubitril/valsartan and clinical outcomes in CRT-D nonresponder patients[J]. J Cardiovasc Pharmacol, 2022, 79(4):472-478. doi: 10.1097/FJC.0000000000001202 URL
[13]	孙劼, 冯力, 董剑廷, 等. 沙库巴曲缬沙坦治疗HFrEF并室性心律失常的疗效研究[J]. 深圳中西医结合杂志, 2021, 31(12):147-149.
[14]	裴强, 王强, 羊镇宇, 等. 沙库巴曲缬沙坦对慢性心力衰竭患者的抗室性心律失常作用[J]. 实用心电学杂志, 2021, 30(5):342-345.
[15]	Curtain JP, Jackson AM, Shen L, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF[J]. Eur J Heart Fail, 2022, 24(3):551-561. doi: 10.1002/ejhf.v24.3 URL
[16]	Medeiros P, Coelho C, Costa-Oliveira C, et al. The effect of sacubitril-valsartan on ventricular arrhythmia burden in patients with heart failure with reduced ejection fraction[J]. Cureus, 2023, 15(2):e34508-e34514.
[17]	El-Battrawy I, Pilsinger C, Liebe V, et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients[J]. J Clin Med, 2019, 8(10):1582. doi: 10.3390/jcm8101582 URL
[18]	Dong Y, Zhai Z, Wang J, et al. Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation[J]. Sci Rep, 2023, 13(1):3140. doi: 10.1038/s41598-023-30349-w pmid: 36823222
[19]	Chen Q, Chen Y, Qin F, et al. Effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:870203.
[20]	Wang Q, Zhuo C, Xia Q, et al. Sacubitril/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation[J]. Cardiovasc Drugs Ther, 2023, 37(3):549-560. doi: 10.1007/s10557-022-07315-1
[21]	Yang L, Zhang M, Hao Z, et al. Sacubitril/valsartan attenuates atrial structural remode-lling in atrial fibrillation patients[J]. ESC Heart Fail, 2022, 9(4):2428-2434. doi: 10.1002/ehf2.13937 pmid: 35437929
[22]	Zhu T, Zhang W, Yang Q, et al. Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:1048077.
[23]	Primessnig U, Deißler PM, Wakula P, et al. Effects of BNP and sacubitrilat/valsartan on atrial functional reserve and arrhythmogenesis in human myocardium[J]. Front Cardiovasc Med, 2022, 9:859014.
[24]	Suo Y, Yuan M, Li H, et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice[J]. Front Pharmacol, 2019, 10:1285. doi: 10.3389/fphar.2019.01285 pmid: 31736759
[25]	Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias[J]. Heart Rhythm, 2014, 11(7):1109-1116. doi: 10.1016/j.hrthm.2014.04.024 pmid: 24837348
[26]	Banasik G, Segiet O, Elwart M, et al. LV mechanical dispersion as a predictor of ventricular arrhythmia in patients with advanced systolic heart failure: A pilot study[J]. Herz, 2016, 41(7): 599-604. pmid: 26883898
[27]	Valentim Gonçalves A, Pereira-da-Silva T, Galrinho A, et al. Antiarrhythmic effect of sacubitril-valsartan: Cause or consequence of clinical improvement?[J]. J Clin Med, 2019, 8(6): 869. doi: 10.3390/jcm8060869 URL
[28]	Sarrias A, Bayes-Genis A. Is sacubitrilat/valsartan(also) an antiarrhythmic drug?[J]. Circulation, 2018, 138(6):551-553. doi: 10.1161/CIRCULATIONAHA.118.034755 pmid: 30354612
[29]	Eiringhaus J, Wünsche CM, Tirilomis P, et al. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail, 2020, 7(5):2992-3002.
[30]	Chang PC, Lin SF, Chu Y, et al. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model[J]. Cardiovasc Ther, 2019, 2019:6032631.
[31]	Tsai YN, Cheng WH, Chang YT, et al. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia[J]. J Cardiol, 2021, 78(4):275-284. doi: 10.1016/j.jjcc.2021.04.011 URL
[32]	Zhou Y, Rui S, Tang S, et al. Exploration of mechanisms of sacubitril/valsartan in the treatment of cardiac arrhythmias using a network pharmacology approach[J]. Front Cardiovasc Med, 2022, 9:829484.
[33]	Murray GL, Colombo J. Sudden cardiac death in the general population: Can we improve risk stratification and prevention?[J]. Int J Angiol, 2021, 30(4):271-276. doi: 10.1055/s-0041-1729629 URL
[34]	Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, angiotensin Ⅱ receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone[J]. Am J Hypertens, 2015, 28(12):1409-1417. doi: 10.1093/ajh/hpv015 URL
[35]	Giallauria F, Vitale G, Pacileo M, et al. Sacubitril/valsartan improves autonomic function and cardiopulmonary parameters inpatients with heart failure with reduced ejection fraction[J]. J Clin Med, 2020, 9(6):189. doi: 10.3390/jcm9010189 URL
[36]	Bunsawat K, Ratchford SM, Alpenglow JK, et al. Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study[J]. Auton Neurosci, 2021, 235:102834.
[37]	Castrichini M, Manca P, Nuzzi V, et al. Sacubitril/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: Standard and advanced echocardiographic evidences[J]. J Clin Med, 2020, 9(4):906. doi: 10.3390/jcm9040906 URL
[38]	Sun Y, Song S, Zhang Y, et al. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure[J]. ESC Heart Fail, 2022, 9(1):667-675.
[39]	李倩, 李昕, 李路安, 等. 沙库巴曲缬沙坦通过逆转高血压大鼠心房结构重塑降低房颤易感性[J]. 中国药理学通报, 2021, 37(5):631-637.
[40]	Li LY, Lou Q, Liu GZ, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J]. Eur J Pharmacol, 2020, 881:173120.
[41]	Li SN, Zhang JR, Zhou L, et al. Sacubitril/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin Ⅱ-induced atrial fibrosis through p-Smad2/3, p-JNK, and p-p38 signaling pathways[J]. J Cardiovasc Transl Res, 2022, 15(1):131-142. doi: 10.1007/s12265-021-10137-5
[42]	Park JJ, Park JH, Hwang IC, et al. Left atrial strain as a predictor of new-onset atrial fibrillation in patients with heart failure[J]. JACC Cardiovasc Imaging, 2020, 13(10):2071-2081. doi: 10.1016/j.jcmg.2020.04.031 pmid: 32682715
[43]	De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: A retrospective cohort study[J]. J Clin Med Res, 2020, 12(2): 100-107. doi: 10.14740/jocmr4076 pmid: 32095179
[44]	Chiu MH, Howlett JG, Kuriachan VP, et al. A case of palpitations due to T-wave oversensing caused by sacubitril/valsartan[J]. Can J Cardiol, 2018, 34(8):1089.e1-1089.e3.
[45]	Vicent L, Juárez M, Martín I, et al. Ventricular arrhythmic storm after initiating sacubitril /valsartan[J]. Cardiology, 2018, 139(2):119-123. doi: 10.1159/000486410 URL
[46]	Vicent L, Méndez-Zurita F, Viñolas X, et al. Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation[J]. Heart Vessels, 2020, 35(1):136-142. doi: 10.1007/s00380-019-01454-6 pmid: 31230095
[47]	Vicent L, Martínez-Sellés M. Can sacubitril/valsartan have a proarrhythmic effect in some high-risk patients?[J]. Cardiology, 2019, 143(1):34-35. doi: 10.1159/000500193 pmid: 31330516
[48]	Weir RAP. Sacubitril/valsartan and mexiletine: A proarrhythmic combination?[J]. Cardiology, 2019, 142(1):4-6. doi: 10.1159/000497071 pmid: 30852576
[49]	Kohjitani A, Miyawaki T, Funahashi M, et al. Mexiletine inhibits nonadrenergic noncholinergic lower oesophageal sphincter relaxation in rabbits[J]. Eur J Pharmacol, 2003, 465(1-2):145-151. pmid: 12650844
[50]	Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: A systems biology approach[J]. NPJ Syst Biol Appl, 2017, 3:12. doi: 10.1038/s41540-017-0013-4 pmid: 28649439
[51]	Vecchio N. Potential drug interactions in critically Ill patients: Sacubitril/valsartan and mexiletine[J]. Cardiology, 2019, 142(2):81-82. doi: 10.1159/000499193 pmid: 31079109
[52]	Langenickel TH, Jordaan P, Petruck J, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization[J]. Eur J Clin Pharmacol, 2016, 72(8):917-924. doi: 10.1007/s00228-016-2062-9 pmid: 27083930
[53]	Okutucu S, Oto A. Electrical storm after initiating sacubitril/valsartan: Arrhythmic paradox[J]. Cardiology, 2019, 142(1):24-25. doi: 10.1159/000496737 pmid: 30865945

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 53

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(1): 75-79.
[2]	Duan Fang, Cui Wei. Application principles of vasodilators in the treatment of acute heart failure [J]. Clinical Focus, 2023, 38(9): 773-778.
[3]	. [J]. Clinical Focus, 2023, 38(9): 832-837.
[4]	. [J]. Clinical Focus, 2023, 38(6): 573-576.
[5]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[6]	. [J]. Clinical Focus, 2023, 38(4): 369-372.
[7]	Zuo Xiuxiu, Hou Tianhua, Wang Hongxiang. Effect of subclinical hypothyroidism on prognosis of patients with chronic systolic heart failure: A meta-analysis [J]. Clinical Focus, 2022, 37(10): 905-911.
[8]	. [J]. Clinical Focus, 2022, 37(9): 838-841.
[9]	Li Heng, Li Yonghui, Sun Xiaoqiang, Wang Lin, He Feng. Efficacy and safety of anticoagulant therapy for patients with heart failure in sinus rhythm [J]. Clinical Focus, 2022, 37(5): 406-411.
[10]	Luo Fanglin, Guan Suying, Wu Guoxiang. Clinical effect of sacubitril-valsartan combined with activin on acute left heart failure [J]. Clinical Focus, 2021, 36(9): 782-785.
[11]	. [J]. Clinical Focus, 2021, 36(7): 641-645.
[12]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[13]	Xu Dongrui, Zhao Qinhui, Liu Tongxiang. Clinical effect of sacubitril/valsartan for heart failure with mid-range ejection fraction in left ventricle [J]. Clinical Focus, 2021, 36(5): 416-420.
[14]	Bai Lian, Guo Peng, Luan Bo, Bai Hao, Jiang Shan. Correlation between serum free fatty acid and cardiac function in patients with acute heart failure [J]. Clinical Focus, 2021, 36(3): 208-211.
[15]	. [J]. Clinical Focus, 2020, 35(12): 1126-1131.